ELIPRODIL

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H23ClFNO
Molecular Weight	347.854
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OC(CN1CCC(CC2=CC=C(F)C=C2)CC1)C3=CC=C(Cl)C=C3

InChI

InChIKey=GGUSQTSTQSHJAH-UHFFFAOYSA-N

InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2

HIDE SMILES / InChI

Molecular Formula	C20H23ClFNO
Molecular Weight	347.854
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

Eliprodil, also known as SL 82-0715, is a non-competitive NMDA glutamate receptor antagonist, which targets the polyamine modulatory site and is selective for NR2B subunit-containing receptors. Eliprodil was in phase III clinical trial for the treatment of stroke or traumatic brain injury. However, these investigations were failed. One reason suggested for failure was that eliprodil had blocked the synaptic transmission mediated by NMDA receptors, hindering neuronal survival. In addition, eliprodil has been studied in phase II clinical trials for the treatment of Parkinson's disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate receptor ionotropic, NMDA 2B 5	Antagonist 2,778		13.0 nM [Ki]
Sigma non-opioid intracellular receptor 1 26	Antagonist 2,778

Conditions

Condition	Modality	Highest Phase	Product
Acute ischemic stroke 19	Primary	Phase III 656	Eliprodil
Parkinson's disease 226	Primary	Phase II 1,132	Eliprodil
Head injury 5	Primary	Phase III 656	Eliprodil
Schizophrenia 298	Primary	Phase I 428	Unknown

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY510425	https://www.001chemical.com/chem/119431-25-3
3B Scientific (Wuhan) Corp	3B3-032330	http://www.3bsc.com/index/pro_info.php?id=53594
AA Blocks	AA000INS	https://www.aablocks.com/goods/Goods/detail?id=AA000INS
AHH Chemical co.,ltd	MT-46887	http://www.ahhchemical.com/product/MT-46887.html
AK Scientific, Inc. (AKSCI)	3607AH	http://www.aksci.com/item_detail.php?cat=3607AH

Showing 1 to 5 of 51 entries

Previous1 2 3 4 5…11Next

PubMed

Show entries

Title	Date	PubMed
NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent.	2001 Apr	11396519
Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.	2010 Mar 12	20226030
Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors.	2010 Nov 2	20462722

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

IV 1.5 mg and 3.0 mg twice daily for 3 days, IV 5.0 mg and 10.0 mg twice daily for 11 days, IV between 2.5 mg and 10 mg per dose, or: 3 mg b.i.d for 3 days iv, followed by 10 mg b.i.d for 11 days p.o and 1,5 mg bid for 3 days i.v, then 5 mg b.i.d for 11 days p.o with 3 month follow-up.

Route of Administration: Other

In Vitro Use Guide

The effect of eliprodil on P-type Ca2+ channels was investigated in acutely dissociated rat Purkinje neurons, by using the whole-cell patch-clamp technique. Eliprodil inhibited in a reversible manner the omega-agatoxin-IVA-sensitive Ba2+ current elicited by step depolarizations from a -80 mV holding voltage (IC50 = 1.9 microM). The Ba2+ current showed steady-state inactivation (V1/2 = -61 mV) which was shifted toward more positive values when the intracellular Ca2+ buffering was increased. In these conditions, the potency of eliprodil was decreased (IC50 = 8.2 microM), suggesting a modulation by intracellular Ca2+ of the eliprodil blockade.